Radiolabelled 177 Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers
Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid-selective nonadentate bispidine ligand suitable for Lu ion complexation. The ligand (bisp,1) was derivat...
Saved in:
Published in | Chemistry : a European journal Vol. 30; no. 14; p. e202303805 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Germany
07.03.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid-selective nonadentate bispidine ligand suitable for
Lu
ion complexation. The ligand (bisp,1) was derivatised with a photoactivatable aryl azide (ArN
) group as a bioconjugation handle for light-induced labelling of proteins. Quantitative radiosynthesis of [
Lu]Lu-1
was accomplished in 10 minutes at 40 °C. Subsequent incubation of [
Lu]Lu-1
with trastuzumab, followed by irradiation with light at 365 nm for 15 min, at room temperature and pH 8.0-8.3, gave the radiolabelled mAb, [
Lu]Lu-1-azepin-trastuzumab ([
Lu]Lu-1-mAb) in a decay-corrected radiochemical yield of 14 %, and radiochemical purity (RCP)>90 %. Stability studies and cellular binding assays in vitro using the SK-OV-3 human ovarian cancer cells confirmed that [
Lu]Lu-1-mAb remained biological active and displayed specific binding to HER2/neu. Experiments in immunocompromised female athymic nude mice bearing subcutaneous xenograft models of SK-OV-3 tumours revealed significantly higher tumour uptake in the normal group compared with the control block group (29.8±11.4 %ID g
vs. 14.8±6.1 %ID g
, respectively; P-value=0.037). The data indicate that bispidine-based ligand systems are suitable starting points for constructing novel, high-denticity chelators for specific complexation of larger radiotheranostic metal ion nuclides. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0947-6539 1521-3765 |
DOI: | 10.1002/chem.202303805 |